News

Michelle Mollica, PhD, RN, discusses training oncology nurses to manage information overload and guide patients post-diagnosis.

FDA approves Pluvicto with ARPI for PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer based on rPFS data.

Handa Oncology received FDA tentative approval for Omcazio capsules, a novel cabozantinib formulation with improved absorption and no food effects.

Learn how supportive culture and connection can improve oncology nurse retention and address burnout, shifting focus from individual responsibility.

Fumiko Chino, MD, discusses strategies for oncology nurses to address unproven treatments like ivermectin while maintaining patient trust.

Learn how healthcare teams can support young adults with cancer as they navigate dating, disclosure, body image, and setting boundaries.

Sunny Pharmtech recalls three lots of Cyclophosphamide for Injection after steel particulates were found, posing risks of thromboembolic events.

A nurse shares her story of balancing 12-hour shifts, pregnancy, and a life-changing lymphoma diagnosis in this From the Floor installment.

Oncology dietitian Gabrielle Raucci explores the role of creatine in cancer care, highlighting when to use it and risks during active treatment.

As ivermectin interest surges via social media, oncology nurses must balance empathetic communication with evidence-based safety and clinical caution.

A study reveals only 18.3% of young adults with advanced cancer receive palliative care, highlighting a critical gap for oncology nurses to address.

New research identifies treatment initiation thresholds that impact 3-year metastasis risk in colorectal cancer patients across distinct pathways.

In the phase 3 RASolute 302 trial, oral KRAS inhibitor daraxonrasib nearly doubled median overall survival to 13.2 months in pancreatic cancer.

Oncology nurses discuss managing lung cancer as a chronic disease, addressing long-term symptoms, financial toxicity, and psychosocial care.

The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance.

A Neurology study reveals breast cancer survivors have a high ischemic stroke risk within one year of diagnosis, linked to specific treatment regimens.

Stephanie Desrosiers discusses strategies for oncology nurses to manage chemotherapy shortages, ensuring patient safety, equity, and mental health.

NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.

A 10-year study of 3,477 patients reveals focal therapy offers high survival and low metastasis for localized prostate cancer with few side effects.

Simone Payette-Capone, RN, discusses balancing protocol with patient care, managing GU trial logistics, and the research nurse's role as a "detective."

NATCO Pharma receives tentative U.S. FDA approval for a generic version of the PARP inhibitor olaparib (Lynparza) for oncology indications.

Kevin Brigle, PhD, ANP, discusses frontline quads, managing toxicities of bispecifics, and the evolving role of nursing in multiple myeloma treatment.

Linda Casey, RN, shares essential strategies for oncology nurses to protect vulnerable patients from the clinical risks of wildfire smoke exposure.

Drs. Sledge and Pastorini discuss how AI-powered molecular profiling corrected a misdiagnosis and the vital "early warning" role of oncology nurses.

FDA approves gedatolisib for HR+/HER2– breast cancer. Learn about the VIKTORIA-1 trial, dosing, and nursing strategies for managing stomatitis.

FDA approves gedatolisib with fulvestrant for adults with HR+/HER2- metastatic breast cancer following endocrine therapy progression.

The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progression.

Czarina Cecilio, BSN, RN, shares roundtable insights on toxicity management, injection techniques, and the critical role of nursing education.